BlueRock Therapeutics LP

In News

FDA grants Orphan Drug designation to BlueRock's RP cell therapy - Eyes On Eyecare

Eyes On Eyecare - Jan 23, 2026

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease - Bayer

Bayer - Oct 07, 2025

First-in-Human Trial of OpCT-001: An iPSC-Derived Cell Therapy for Primary Photoreceptor Diseases - BioInformant

BioInformant - Jul 25, 2025

First Parkinson’s disease patient treated in BlueRock’s pivotal Phase III trial of investigational cell therapy bemdaneprocel - Bayer

Bayer - Sep 22, 2025

Japan approves first iPSC therapy for Parkinson’s disease - BioWorld News

BioWorld News - Mar 06, 2026

Bayer-owned BlueRock lays off 50 employees, shutters Cambridge research labs - Fierce Biotech

Fierce Biotech - Jun 25, 2025

BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial - PR Newswire

PR Newswire - Mar 14, 2023

BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel - CGTLive®

CGTLive® - Jul 22, 2024

BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan - Bayer

Bayer - Dec 17, 2025

BlueRock Therapeutics and Foundation Fighting Blindness collaborate to add new cohort to Uni-Rare study evaluating inherited retinal diseases - Ophthalmology Times

Ophthalmology Times - Mar 25, 2024

BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics - PR Newswire

PR Newswire - Jan 23, 2024

BlueRock Receive FDA clearance of IND for Investigational iPSC-derived Cell Therapy OpCT-001 - BioInformant

BioInformant - Sep 09, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment